ScinoPharm Taiwan Ltd (1789)

Currency in TWD
25.50
-2.00(-7.27%)
Closed·
Unusual trading volume
1789 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.5027.45
52 wk Range
16.2529.10
Key Statistics
Bid/Ask
27.10 / 27.15
Prev. Close
21
Open
26.5
Day's Range
25.5-27.45
52 wk Range
16.25-29.1
Volume
6.37M
Average Volume (3m)
1.5M
1-Year Change
13.3333%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1789 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.00
Downside
-29.41%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

ScinoPharm Taiwan Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

ScinoPharm Taiwan Ltd Company Profile

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CDMO services, such as contract analytical testing services, sterile injectables contract manufacturing, small molecules CDMO service, peptide CDMO service, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates, as well as develops peptide synthesis technologies. In addition, the company develops and manufactures western medicines and other chemical materials, albumin and oligonucleotide medicines, and injections, as well as provides biological technology services, technical, and intellectual property rights related services. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

Employees
540
Market
Taiwan

Compare 1789 to Peers and Sector

Metrics to compare
1789
Peers
Sector
Relationship
P/E Ratio
104.5x40.3x−0.6x
PEG Ratio
−1.991.700.00
Price/Book
1.8x4.0x2.6x
Price / LTM Sales
6.3x7.0x3.4x
Upside (Analyst Target)
−29.4%9.5%44.4%
Fair Value Upside
Unlock−3.1%6.1%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 18.00
(-29.41% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.24%
Dividend Yield
1.42%
Industry Median 2.57%
Annualized payout
0.35
Paid annually
5-Years Growth
+5.33%
Growth Streak

Earnings

Latest Release
Nov 03, 2025
EPS / Forecast
0.10 / 0.10
Revenue / Forecast
800.00M / 800.00M
EPS Revisions
Last 90 days

1789 Income Statement

FAQ

What Is the SPT (1789) Stock Price Today?

The SPT stock price today is 25.50

What Stock Exchange Does SPT Trade On?

SPT is listed and trades on the Taiwan Stock Exchange stock exchange.

What Is the Stock Symbol for SPT?

The stock symbol for SPT is "1789."

Does SPT Pay Dividends? What’s The Current Dividend Yield?

The SPT dividend yield is 1.42%.

What Is the SPT Market Cap?

As of today, SPT market cap is 20.16B.

What Is SPT's Earnings Per Share (TTM)?

The SPT EPS (TTM) is 0.24.

When Is the Next SPT Earnings Date?

SPT will release its next earnings report on Mar 04, 2026.

From a Technical Analysis Perspective, Is 1789 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has SPT Stock Split?

SPT has split 6 times.

How Many Employees Does SPT Have?

SPT has 540 employees.

What is the current trading status of SPT (1789)?

As of Jan 30, 2026, SPT (1789) is trading at a price of 25.50, with a previous close of 21.00. The stock has fluctuated within a day range of 25.50 to 27.45, while its 52-week range spans from 16.25 to 29.10.

What Is SPT (1789) Price Target According to Analysts?

The average 12-month price target for SPT is TWD18.00, with a high estimate of TWD18 and a low estimate of TWD18. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an -29.41% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.